Key Points
- Insider purchase: Director Peter John Harrison bought 1,065 shares on April 8 at an average of GBX 1,849 per share, a transaction totalling £19,691.85.
- Recent results: Bioventix reported quarterly EPS of GBX 69.38 with a net margin of 59.30% and return on equity of 65.83%, and sell-side analysts forecast about 166.31 EPS for the current year.
- Stock/valuation: Shares opened at GBX 1,890, the company has a market cap of £98.75 million and a P/E of 13.45, with a 52‑week range of GBX 1,300 to 3,020 and 50/200-day moving averages of GBX 1,602.29 and GBX 1,883.90 respectively.
Bioventix PLC (LON:BVXP - Get Free Report) insider Peter John Harrison acquired 1,065 shares of Bioventix stock in a transaction dated Wednesday, April 8th. The stock was purchased at an average cost of GBX 1,849 per share, for a total transaction of £19,691.85.
Bioventix Stock Performance
LON:BVXP opened at GBX 1,890 on Friday. The firm's fifty day moving average is GBX 1,602.29 and its 200-day moving average is GBX 1,883.90. Bioventix PLC has a 52 week low of GBX 1,300 and a 52 week high of GBX 3,020. The firm has a market cap of £98.75 million, a P/E ratio of 13.45 and a beta of 0.48.
Bioventix (LON:BVXP - Get Free Report) last posted its quarterly earnings data on Monday, March 30th. The biotechnology company reported GBX 69.38 EPS for the quarter. Bioventix had a net margin of 59.30% and a return on equity of 65.83%. The company had revenue of GBX 615.88 billion for the quarter. As a group, sell-side analysts anticipate that Bioventix PLC will post 166.3066955 earnings per share for the current year.
Bioventix Company Profile
(
Get Free Report)
Bioventix PLC creates, manufactures, and supplies sheep monoclonal antibodies (SMAs) for diagnostic applications worldwide. The company offers a portfolio of purified SMAs for thyroid, vitamin D, cardiac, drugs of abuse, fertility, oncology, and miscellaneous indications; and Pyrene (HOP-G) ELISA kit to monitor human exposure to industrial pollutants. It also provides contract SMAs and recombinant services. Bioventix PLC was incorporated in 2003 and is based in Farnham, United Kingdom.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
